{"entity":{"id":"nct05652920","kind":"trial","name":"Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC","aka":[],"tldr":"A phase 1/2 trial of Ori-C101 in hepatocellular carcinoma, run by OriCell Therapeutics Co., Ltd., now recruiting.","summary":"Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC is a phase 1/2 interventional study registered as NCT05652920 by OriCell Therapeutics Co., Ltd., with 105 participants planned, started 2022-12-15 and due to reach its primary completion in 2026-12. Interventions recorded: Ori-C101.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05652920","url":"https://clinicaltrials.gov/study/NCT05652920"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05652920","phase":"1/2","setting":"A Phase Ib/II, Open-Label, Multi-Center Study to Investigate the Safety, PK, and Efficacy of Ori-C101 in Advanced Hepatocellular Carcinoma (HCC) Patients (BEACON)","sponsor":"OriCell Therapeutics Co., Ltd.","enrolled":105,"outcomes":[]},"route":"/trials/nct05652920/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}]}}